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ABSTRACT
Triple negative breast cancer (TNBC) is still associated with grave prognosis, 
especially compared to other breast cancer subtypes. Advances in medical 
science have improved our understanding on the biological nature and 
heterogeneity of TNBC, explaining the efficacy variability of existing 
chemotherapeutic drugs on TNBC patients. Complexity of TNBC has led to 
wide variation of TNBC treatment across the globe, resulting in unsatisfactory 
treatment outcome. This issue is further complicated by the absence of 
TNBC treatment guideline in many countries, including in Indonesia. This 
review discusses systemic treatment options for TNBC while taking account 
its molecular heterogeneity. Specific consideration is made for Indonesia, 
not only for current clinical practice, but also for future improvements. 
Immunotherapy, especially programmed cell death 1 (PD-1/PD-L1) inhibitor, 
has recently shown promising result in TNBC patients. It can be concluded that 
TNBC is heterogenous and treatment option should be tailored based on its 
molecular profile.
ABSTRAK
Kanker payudara tripel negatif (KPTN) masih berhubungan dengan kesintasan 
yang buruk, terutama jika dibandingkan dengan subtipe kanker payudara 
lainnya. Kemajuan teknologi telah meningkatkan pemahaman kita tentang 
sifat biologis dan heterogenitas KPTN yang merupakan dasar dari variabilitas 
respon pasien KPTN terhadap kemoterapi. Kompleksitas KPTN menyebabkan 
terjadinya perbedaan dan variasi dari pola pengobatan KPTN di seluruh 
dunia dan berdampak pada hasil pengobatan yang belum memuaskan. Hal 
ini diperburuk dengan tidak adanya panduan terapi KPTN di banyak negara, 
termasuk di Indonesia. Tinjauan ini membahas tentang pilihan terapi sistemik 
untuk pasien KPTN dengan mempertimbangkan heterogenitas molekuler 
pada subtipe ini. Perhatian khusus ditujukan pada Indonesia, baik untuk 
tatalaksana saat ini maupun untuk kemajuan di masa depan. Imunoterapi, 
khususnya programmed cell death 1 (PD-1/PD-L1) inhibitor, menunjukkan hasil 
yang menjanjikan pada pasien KPTN.Dapat disimpulkan bahwa KPTN bersifat 
heterogen dan pemilihan modalitas terapi sebaiknya disesuaikan dengan 
profil molekuler pasien.
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INTRODUCTION
Triple negative breast cancer 
(TNBC) accounts for 10 – 20% of all 
breast cancers which roughly translates 
into 200.000 of new cases annually 
worldwide.1,2 Epidemiological data of 
Indonesian showed that TNBC patients 
is very rare. According to reports from 
Widodo et al.3 and Sitohang et al.,4 TNBC 
accounts for 20-25% of all breast cancer 
cases in Dr. Sardjito General Hospital, 
Yogyakarta, Indonesia. TNBC is a very 
heterogeneous disease with wide variety 
of genetic expression and mutations. 
Collectively TNBC has the worst survival 
compared to other breast cancer 
subtypes. Existing treatment modalities 
still do not result in acceptable survival 
outcome.5 Although both ESMO and 
ASCO (NCCN) have published treatment 
guidelinesfor TNBC,there is still no 
standard chemotherapy regimenfor 
TNBC, leading to wide variation of TNBC 
treatment across the globe.6-8
In Indonesia, TNBC patients are 
mainly treated surgically followed 
by adjuvant chemotherapy. Since 
currently there is no guideline for TNBC 
treatment in Indonesia, Indonesian 
health professionals have to adapt 
and implement multiple international 
guidelines into their daily practice, 
albeit with limited success. The lack of 
consensus on choosing chemotherapy 
regimen for TNBC patients in Indonesia 
further complicates this issue. The aimed 
of this review paper was to provide 
recommendation and suggestion for the 
development of Indonesian guideline 
on TNBC treatment as well as for other 
developing countries that donot have 
such guideline at the moment.
LITERATURE REVIEW
TNBCheterogeneity
TNBC is immunohistochemically 
defined as the lack of estrogen receptor 
(ER) and progesterone receptor (PR) 
expression accompanied with the lack 
of human epidermal growth FACTOR 
receptor2 (HER2) overexpression.9 
According to American society of clinical 
oncology/college of American pathologist 
(ASCO/CAP) guidelines, ER and PR 
expression have to be ≤ 1% for them to 
be considered as negative.10 Classifying 
TNBC according to IHC is not enough 
as the heterogeneity of TNBC extend 
beyond ER, PR, and HER2 expression 
alone. Multiple attempts have been done 
to improve the classification of TNBC 
with the most widely discussed at the 
moment being classification by Perou 
et al.11 (PAM50) and Lehmann et al.12 
(Vanderbilt).12-16
Perou et al.11 provided the first 
insight on “intrinsic subtypes” of breast 
cancer based on gene expression 
profiling analysis. Perou et al.11 came 
up with 4 intrinsic subtypes of breast 
cancer, namely luminal, HER2-enriched, 
basal-like and normal breast-like. Breast 
cancer subtypes according to Perou’s 
classification was further added by 
research done by Sørlie et al.12 which 
divided luminal subtypes into luminal 
A and B. Prat et al.17 added Claudin 
Low subtype. Throughout the years, 
this classification has been intensively 
studied and has showed clinical and 
prognostic significance, albeit limited.12-15 
Prat et al.14 later refined the 6 subtypes 
classification into 2 subtypes, basal-like 
and non-basal-like.
Lehmann et al.18 initially classified 
TNBC into 6 subtypes (also known as 
TNBC type), namelybasal-like 1 and 2 
(BL1 and BL2), immunomodulatory 
(IM), mesenchymal (M), mesenchymal 
stem–like (MSL), and luminal androgen 
receptor (LAR). Further research then 
considered IM and MSL subtypes to had 
been defined by the high expression of 
genes from the tumor microenvironment 
and not from the actual tumor cells, 
leading to the omission of IM and MSL 
subtypes from the refined classification, 
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also known as TNBCtype-4.14,16 Masuda et 
al.19 investigated the clinical relevance 
of the original Vanderbilt classification 
(TNBCtype) in neoadjuvant setting with 
anthracycline and taxane chemotherapy. 
They found that BL1 subtype had the 
highest pathologic complete response 
(pCR) rate (52%) and BL2 and LAR had 
the lowest (0 and 10%, respectively).
Although Perou et al,11 (later refined 
by Pratet al.14) and Lehmann et al.16 
came up with different classifications, 
both shared some overlapping entities. 
Both classifications came up with 3 basic 
subtypes, mesenchymal, basal-like, and 
LAR in Vanderbilt classification and 
Claudin-low, basal-like and luminal/
HER2E in PAM50 classification.14 Apart 
from significant scientific contribution, 
neither of the two classifications can 
fully describe the heterogeneity of 
TNBC’s biological characteristic which 
causes more researchers to try to 
find a better classification of TNBC. 
Burstein et al.20 thought gene profiling 
alone might not be enough to classify 
TNBC and attempted to combine gene 
profiling with transcriptomic analysis 
according to mRNA to classify TNBC 
(Baylor classification). Burstein et al,20 
classified TNBC into 4 subtypes, namely: 
luminal-AR (LAR), mesenchymal (MES), 
basal-like immune-suppressed (BLIS), 
and basal-like immune-activated (BLIA). 
Out of the four subtypes, BLIS subtype 
has the best prognosis for both DFS and 
DSS while BLIA has the worst. According 
to Burstein et al,20 Baylor classification 
does havesome similarities with both 
Vanderbilt and PAM50 classifications. 
The LAR subtype in Baylor classification 
is very similar with LAR subtype in 
Vanderbilt classification while both 
BLIS and BLIA subtypes from Baylor 
classification are entirely classified 
asbasal-like according to PAM50 
classification.20 
Current classifications of TNBC 
allow researchers to systematically 
analyze treatment effect on different 
TNBC subtypes. Although useful in 
clinical trials, more evidence is needed to 
establish the prognostic and therapeutic 
value of these classifications.
TNBC in Asian population
Race and ethnic group are known to 
influence characteristic and prognosis 
of TNBC.21 Compared to America, India 
has higher prevalence of TNBC (>30% 
of all breast cancer) and is associated 
with younger age at diagnosis and 
worse prognosis.22-25 Different pattern is 
observed in Chinese population. China 
has one of the lowest prevalence of 
TNBC among Asian countries (around 
10.4-13.5% of all breast cancer) with 
significantly better survival compared 
to other population (5- and 10-year 
OS were as high as 79.92 and 82%, 
respectively).26,27 Currently, there is no 
data of TNBC survival in Indonesian 
patients, although the incidence is 
around 20-25% of all breast cancer 
cases, relatively high compared to other 
countries.3,4
TNBC treatment modalities Local 
control
Surgery and radiotherapy in TNBC 
are principally similar with other breast 
cancer subtypes and will not be discussed 
in this paper.
Systemic therapy
Systemic chemotherapy, both as 
adjuvant and neoadjuvant therapy, 
is the main treatment of TNBC. All of 
the chemotherapy regimens used in 
breast cancer in general can be used in 
TNBC with anthracycline- and taxane- 
based chemotherapy being the more 
preferred option for both adjuvant and 
neoadjuvant settings.28-30
Platinum salt
Addition of platinum salt towards 
standard chemotherapy regimen had 
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been proven to improve survival in 
TNBC patients. CALGB 40603 trial 
showed that addition of carboplatin to 
standard regimen (paclitaxel 80 mg/
m2 once a week for 12 weeks, followed 
by doxorubicin plus cyclophosphamide 
once every 2 weeks for four cycles) 
significantly increased pCR breast (60% 
vs. 44%; p=0.0018) and pCR breast/axilla 
(54% vs. 41%; p=0.0029).31 Follow-up 
analysis of CALGB 40603 trial reported 
that three-year overall EFS was 74.1% 
and OS 83.2%. Patients who achieved 
pCR breast had significantly better three-
year EFS compared to those who did not 
(84.8% vs. 61.8%).32 Although it should 
be noted that the addition of carboplatin 
or bevacizumab significantly increased 
chemotherapy-related toxicity which 
decreased the chance for patients to 
complete the standard chemotherapy 
regimen without skipped doses, dose 
modification, or early discontinuation.
Similar with CALGB 40603 trial, 
GeparSixto trial also showed that the 
addition of carboplatin to standard 
regimen (18 weeks of paclitaxel 80 mg/
m2 once a week and non-pegylated 
liposomal doxorubicin 20 mg/m2 once 
a week) increased pCR rate in TNBC 
patients (53.2% vs. 58%; p=0.005) but not 
in HER2-positive breast cancer. Increased 
incidence of chemotherapy associated 
toxicity due to the addition of carboplatin 
also observed in GeparSixto trial.33 
Comparing 2 of the most commonly used 
platinum agents in treating metastatic 
TNBC patients, phase II TBCR009 trial 
found that cisplatin had abetter response 
rate compared to carboplatin (32.6% vs. 
18.7%). The overall response rate for 
both agents combined was 25.6% and 
was particularly high in individuals with 
BRCA1/2 mutations compared to the ones 
without the mutation (54.5% vs. 19.7%).34 
Long term follow-up showed that stage II/
III TNBC patients treated with paclitaxel 
(175 mg/m2, day1) plus carboplatin (area 
under the curve = 5, day2) resulted in 
significantly higher five-yearrecurrence-
free survival (RFS) compared to patients 
treated with epirubicin (75mg/m2, day1) 
plus paclitaxel (175mg/m2, day2) (EP) 
(77.6% vs. 56.2%; p=0.014). Five-year OS 
were not significantly different between 
2 treatment arms (83.3% vs. 70.7%; 
p=0.350). Patients who achieved pCR had 
significantly better five-year RFS (94.7% 
vs. 56.1%; p=0.043) and OS (100.0% vs. 
67.2%; p=0.004).35
The effectiveness of platinum 
salt in treating TNBC is thought to be 
caused by formation of DNA-platinum 
adducts which leads to inter- and intra- 
strand cross-links. This cross-linking 
of DNA interferes with replication 
and transcription which results in the 
breaking of a double-stranded DNA strand 
and ultimately results in cell death.36 
Platinum is especially effective in TNBC 
with BRCA1 germline mutation because 
BRCA1 is a mediator of homologous 
recombination (HR) and mutation of 
BRCA1 leads to decreased DNA repair 
and DNA stability. Byrski et al.37 observed 
90% pCR rate in 10 patients with BRCA1 
mutation (9 TNBC, 1 incomplete data) 
treated with cisplatin (75mg/m2 every 
3weeks for four cycles). Effectiveness 
of platinum in BRCA mutated patients 
is further elucidated in another study 
by Byrski et al.37 In this study 102 BRCA1 
mutation carriers were treated with 
different chemotherapy regimens and 
the highest pCR rate was achieved in 
patients treated with cisplatin (83%), 
followed by AC/FAC regimen (22%), AT 
regimen (8%), and CMF regimen (7%). 
Although positive results have been 
seen in BRCA1 mutated TNBC patients, 
BRCA1 mutation is found only in 23-
57% of all TNBC cases.38,39 Incidence 
of BRCA mutation seems to be varied 
according to race and country.40 Nanda 
et al.41 observed that BRCA mutations 
were highest among Ashkenazi Jewish 
families, followed by Caucasians and 
African Americans (69.0, 46.2, and 27.9% 
respectively). In Indonesia, studies 
have showed that BRCA mutations 
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occurred in 0-7.8% of all breast cancer 
patients,42,43 which is similar with other 
Asian countries.44,45 Furthermore, BRCA1 
mutation represent only a fraction of 
basal-like subtype according to PAM50 
or BL1 and BL2 according to Vanderbilt 
classification which means there is still 
a huge proportion of TNBC patients 
that requires different treatment 
approach.14,18
PARP inhibitor
Poly (ADP-ribose) polymerase (PARP) 
is important in facilitating base excision 
repair (BER).46 As BER is essential in single-
strand DNA breaks repair, inhibition 
of PARP may lead to accumulation of 
DNA single-strand breaks, which in the 
absence of double-strand homologous 
recombinant (HR) repair mechanism, 
causes “synthetic lethality”.47 In many 
breast cancer cases, including TNBC, 
double-strand HR repair defect is 
associated with BRCA1 mutation.38,39,48 
Since PARP is highly expressed in more 
than 80% of BRCA1 mutated TNBC 
patients, inhibition of PARP is thought to 
add benefit in treatment of TNBC.49,50
The positive impact of PARP inhibitor 
in the treatment of TNBC patients was 
shown in a phase II trial by O’Shaughnessy 
et al.51 This study found that the 
addition of iniparib to gemcitabine and 
carboplatin improved the rate of clinical 
benefit from 34 to 56% (p=0.01) and the 
rate of overall response from 32 to 52% 
(p=0.02). The median progression-free 
survival (PFS) and overall survival (OS) 
were also prolonged with the addition 
of iniparib (3.6 vs. 5.9 months and 7.7 
vs. 12.3 months respectively). However, 
the positive result from phase II trial 
did nottranslate very well in the phase 
III confirmation trial as the addition of 
iniparib to gemcitabine and carboplatin 
showed that improved OS (HR 0.65, 
95%CI: 0.46-0.91) and PFS (HR 0.68; 
95%CI: 0.50-0.92) only seen when the 
regimen was given as second-/third-line 
treatment.52
Other types of PARP inhibitor have 
been tested in clinical trials and showed 
positive result in treating TNBC. A report 
published from I-SPY 2 trial showed that 
addition of carboplatin and veliparib 
to standard chemotherapy regimen [12 
cycles of weekly paclitaxel followed by 
doxorubicin/cyclophosphamide (AC)  X 
4] increased pCR rate of TNBC patients 
(51% vs. 26%) with 88% predicted 
probability of phase 3 success.53 A phase 
III trial of 302 patients by Robson et al.54 
found that olaparib (PARP1 and PARP2 
inhibitor) improves the outcome of 
metastatic breastcancer patients with 
BRCA mutation. Median progression-free 
survival was significantly longer in the 
olaparib group compared to the standard-
therapy group (7.0 vs. 4.2 months; PFS: 
HR 0.58, 95%CI: 0.43-0.80). The response 
rate was 59.9% in the olaparib group 
and 28.8% in the standard-therapy 
group with sub analysis result showing 
significantly better response in TNBC 
patients compared to hormone-receptor 
positive patients/HR 0.43 (95%CI: 0.29-
0.63) vs 0.82 (95%CI: 0.55-1.26).54
EGFR inhibitor
Epidermal growth factor receptor 
(EGFR),a member of ErbB family of 
receptor tyrosine kinasehas been 
showed to be important contributor 
oftumor cell proliferation, migration, 
and survival.55-58 Research has showed 
that EGFR expression tend to be higher 
in TNBC patients when compared to non-
TNBC patients, is more frequently seen in 
basal subtype and associated with worse 
prognosis.14,18,59-61 However, reports on 
the frequency of EGFR overexpression 
in TNBC have been varied (13-89%), with 
lower frequency particularly observed 
in Korean patients (13-30%), suggesting 
EGFR overexpression might be influenced 
by race.60,62,63 As EGFR is involved in 
various carcinogenesis processes and is 
highly expressed in TNBC, the addition 
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of EGFR inhibitor theoretically will 
add benefit in TNBC patients. Despite 
promising results in preclinical studies, 
results from clinical trials have been 
lackluster at best. Most trials reported 
that the addition of EGFR inhibitor didn’t 
result in significant clinical response 
in advanced TNBC patients and was 
associated with increased incidence 
of chemotherapy-related side effects, 
especially hematological toxicities.64-67 
The only clinically significant result of 
EGFR inhibitor so far was reported by 
Carey et al.68 with 6% response rate (RR) 
shown in the addition of cetuximab 
in metastatic TNBC treatment, while 
cetuximab plus carboplatin resulted in 
16% RR after progression. Disappointing 
results from clinical trials makes it 
difficult to suggest the usage of EGFR 
inhibitor in TNBC treatment. However, 
because further research on this topic 
is ongoing, the role of EGFR inhibitor in 
management of TNBC patients has not 
been determined.
Androgen receptor inhibitor
Androgen receptor (AR) is expressed 
in all of breast cancer subtypes, 
including TNBC.69-72 Researchhas shown 
that AR is expressed in 12-53% of all 
TNBC patients.72-75 The wide frequency 
difference of AR expression between 
studies is partly explained by the 
absence of standardized method of 
determining AR positivity. AR negativity 
in TNBC is associated with younger age 
at diagnosis and worse prognosis in 
African American women. Classification 
of TNBC by Lehmann et al.16 and Burstein 
et al.20 grouped AR expressing TNBC as a 
separate entity (LAR subtype). This LAR 
subtype was observed to have lower 
rate of response towards neo-adjuvant 
chemotherapy, suggesting the need for 
different treatment approach towards 
this subtype.19
Due to the success of targeting 
estrogen and progesterone receptors 
in treating hormone positive breast 
cancer, research on the effectiveness of 
AR inhibitor in treating breast cancer, 
especially TNBC became more prevalent. 
As a proof of concept for the role of AR 
inhibitor in treating TNBC, Gucalp et al.75 
reported that bicalutamide showed 19% 
clinical benefit rate (CBR) when given to 
ER-PR- metastatic breast cancer patients. 
Similar with previous study, Bonnefoi 
et al,76 reported that the addition of 
abiraterone acetate (AA) and prednisone 
resulted in 20% CBR and 6.7% objective 
response rate (ORR)in advanced AR+ 
TNBC patients.More recently, a phase 
II study by Traina et al.77 reported that 
enzalutamide resulted in 33.3% of CBR 
when given to AR+ TNBC patients treated 
with 0-1 prior lines of therapy with 
fatigue as the only grade 3 or higher drug 
related toxicity.
PD-1/PD-L1inhibitor
Programmed death 1 receptor (PD-1) 
is an immune checkpoint receptor and 
when bound to its PD-L1 ligand, results 
in immunoinhibitory response which 
contributes to cancer cell survival and 
progression.78-81 In cases of cancer that 
expresses PD-1/PD-L1, inhibition of PD-1/
PD-L1 results in cancer cell death. Studies 
have shown that PD-1/PD-L1 expression 
in TNBC tend to be higher when compared 
to non-TNBC with estimated frequency 
of 20-58% in all of TNBC patients.82-86 
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High expression of PD-1/PD-L1 has been 
associated with high expression of TILs, 
including in TNBC.87 Higher expression of 
TILs is associated with better survival in 
TNBC patients, suggesting the potential 
of PD-1/PD-L1 inhibitor as a candidate 
for TNBC treatment.88
Promising results have been seen in 
clinical studies of PD-1/PD-L1 inhibitor in 
TNBC treatment. A phase 1b KEYNOTE-012 
study by Nanda et al.83 reported that 
single agent pembrolizumab (10 mg/kg 
every 2 weeks) treatment in advanced 
TNBC patients resulted in 18.5% ORR 
accompanied by generally mild drug 
related toxicity, although 15.6% of 
the patients experienced grade ≥ 3 
toxicity and one patient died due to 
treatment-related cause. In phase II 
study, Nanda et al.89 reported that the 
addition of pembrolizumab increased 
the raw pCR rate by 52.1% (19.3 to 
71.4%) and estimated pCR rate by > 40%, 
with predicted probability of success 
in phase III trial of 99.3%. Immune 
related toxicities were observed in 5 
of 69 patients included in this study, 
which were hypophysitis (I patient) and 
adrenal insufficiency (4 patients).Given 
as first line therapy in metastatic TNBC 
patients, pembrolizumab (200 mg Q3W) 
monotherapy showed 23% ORR with 
manageable safety profile.90
Other trials have also showed 
similarly positive results of PD-1/PD-L1 
inhibitor in advanced TNBC patients. A 
phase 1b KEYNOTE-173 study by Schmid 
et al,84 reported overall ORR (CR+PR) 
before surgery of 80% (90% CI: 49-96) in 
A (single-dose pembrolizumab followed 
by 4 cycles of pembrolizumab Q3W + 
nab-paclitaxel (Np) weekly followed 
by 4 cycles of pembro + doxorubicin + 
cyclophosphamide Q3W)and 100% (90% 
CI, 74-100) in B (same as in A but with 
carboplatin Q3W added to pembro + Np). 
ypT0/Tis pCR rate was 70% (90% CI: 39-
91) in A and 100% (90% CI: 74-100) in B; 
ypT0 ypN0 pCR rate was 50% (90% CI: 
22-78) in A and 90% (90% CI: 61-100) in 
B; and yT0/Tis ypN0 pCR rate was 60% 
(90% CI, 30-85) in A and 90% (90% CI: 
61-100) in B.A phase Ib trial by Adams et 
al,91 showed that atezolizumab (800 mg 
Q2W; d1,15) and nab-paclitaxel (125 mg/
m2 Q1W; d1,8,15, q3 of 4 weeks) resulted 
in 42% confirmed ORR. PD-1/PD-L1 
inhibitor is perhaps the most promising 
immunotherapy agent for TNBC that we 
have so far, although more evidence is 
still needed to support routine use of this 
agent for TNBC treatment.
Eribulin
Eribulin, a microtubule inhibitor, 
recently has shown positive results 
when given to TNBC patients. A phase 
III clinical trial assessing the effect of 
eribulin on pretreated metastatic breast 
cancer showed that the addition of 
eribulinmesylate 1.4 mg/m2 significantly 
improved PFS (HR 0.77; 95% CI: 0.60-0.97; 
p=0.028) and OS (HR 0.72; 95% CI:0.57-
0.90; p=0.005) in TNBC patients.92 In 
another study, Manikhas et al.93 observed 
that metastatic TNBC patients treated 
with erbulin resulted in 9.6% of clinical 
ORR and 46.1% stable disease with 
relatively well tolerated drug related 
toxicity. More recently, a phase Ib/II trial 
showed that eribulin in combination 
with pembrolizumab resulted in ORR of 
29.2% (95% CI: 18.6-41.8) when given to 
metastatic TNBC patients (Eisai Co Ltd, 
2017).94
88
J Med Sci, Volume 52, Number 1, 2020 January: 81-101
TABLE 1. Summary of considerations in choosing treatment options
Treatment option Consideration
Anthracyline + 
taxane chemotherapy
Generally, is the regimen of choice for initial treatment, both in 
neoadjuvant and adjuvant setting. 28-30
Platinum salt Generally sensitive for TNBC, is associated with the best outcome 
compared to other systemic chemotherapy regimen, especially in 
BRCA1(+). Can be used as 1st line agent.31-35, 37
PARP inhibitor Improves survival when given in combination with platinum-based 
chemotherapy, possibly through “synthetic lethality.” 51-54
EGFR inhibitor Theoretically will add benefit in TNBC patient. Phase II studies have 
shown small but significant clinical response. Currently evidence is 
still lacking to support routine use of this agent to treat TNBC.64-68
AR inhibitor Androgen receptor is known to be expressed in some TNBC patients.69-72 
Phase II studies have shown moderate clinical response.75-76 More 
evidence is required to understand its role in TNBC treatment.
PD-1/PDL-1 inhibitor Promising agent for TNBC treatment. Multiple phase II studies have 
shown positive result in metastatic setting when used in combination 
with other chemotherapy agents.89-90
Eribulin Moderate response is observed when given to metastatic patients. 
Although its role in improving survival, especially in early stage 
TNBC, is unknown.92-94
TP53 inhibitor
TP53, a tumor suppressor gene, 
is one of the most frequently found 
mutated gene in TNBC (64-82%) and is 
often associated with worse response 
to treatment and survival.85,95-97 TP53 
has been hypothesized as one of the 
most important driving forces in 
carcinogenesis of TNBC, suggesting 
its potential as a therapeutic target.98 
Preclinical studies have shown positive 
effect of TP53 inhibition in TNBC cell 
lines, albeit have not been validated 
by clinical trials.99 Currently, two anti-
TP53 drugs, APR-246 and COTI-2 are 
undergoing phase I clinical trials on 
other types of cancer that show high 
rate of TP53 mutation, showing tolerable 
toxicity, and promising efficacy.100,101
MiRNA inhibitor
Inhibition of miRNA has been 
discussed as an option to treat TNBC as 
it is known that certain types of miRNA 
are associated with the survival of TNBC 
patients. Meta-analysis by Lü et al.102 
showed that decreased expression of 
miR-155 and increased expression of 
miR-21 were predictive of reduced OS. 
Lü et al.102 also found that elevated levels 
of miR-27a/b, miR-210, and miR-454 
expression were associated with shorter 
OS, while the levels of miR-454 and miR-
374a/b expression were associated with 
DFS. A study by Svoboda et al,103 observed 
that miR-34b expression negatively 
correlated with DFS and OS in TNBC 
patients. Research on the therapeutic 
role of miRNA for TNBC is currently in 
preclinical phase. Li et al.3 reported that 
miR-454 promoted and enhanced the 
proliferation, migration and invasion of 
TNBC cells. Overexpression of miR-454 
inhibited TNBC cell death by ionizing 
radiation through the regulation of 
caspase 3/7 and Bcl-2 expression. 
Chen et al.104 observed that miR-211-
5p was significantly down regulated 
in TNBC and its expression level was 
associated with overall survival in 
TNBC. The expression of miR-211-5p 
suppressed TNBC cell proliferation, 
invasion, migration and metastasis in 
vitro and in vivo. Although there is no 
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targeted therapy aimed specifically at 
certain miRNA, recent reports have 
shown that the serum level of various 
miRNA is affected by chemotherapy 
and might be associated with patient 
survival, suggesting their involvement 
in healing process. There is substantial 
amount of miRNA which are potential 
targets for future TNBC therapy.105-108 
Unfortunately, we have not reached 
adequate understanding on the best 
way to target miRNA to treat TNBC, thus 
significant progress from preclinical 
studies is needed before we can move 
on to clinical trials.
PI3K/AKT/mTOR inhibitor
Phosphoinositide 3-kinase (PI3K)/
protein kinase B (AKT)/mechanistic 
target of rapamycin (mTOR) is one of 
the most important pathways in cell 
survival, proliferation, and metastasis of 
certain cancers.109-111 During the creation 
of theirclassification, Lehmann et al.18 
observed that multiple components of 
PI3K/AKT/mTOR pathway were mutated 
in some TNBC patients, especially the 
ones classified into mesenchymal-like 
and mesenchymal stem-like subtypes. 
In recent years many discussions 
had taken place discussing whether 
inhibition of PI3K/AKT/mTOR pathway 
would lead to better survival in TNBC 
patients. Preclinical studies have shown 
that multiple agents targeting various 
points in PI3K/AKT/mTOR pathway 
have resulted in growth arrest of 
TNBC cell lines.112-114 At the moment, 
there are numerous trials underway 
assessing PI3K/AKT/mTOR inhibitors 
in TNBC patients. Using metaplastic 
TNBC as a surrogate for mesenchymal 
TNBC, aphase I trial showed that the 
combination of liposomal doxorubicin, 
bevacizumab, and temsirolimus or 
everolimusresulted in 21% ORR (8% 
CR, 13% PR) and 19% stable disease for 
at least 6 months, for a clinical benefit 
rate of 40%. The presence of PI3K 
pathway aberration was associated with 
a significant improvement in ORR (31 
vs. 0%; p=0.04) but not CBR (44 vs. 45%; 
p > 0.99).115 Although not yet proven to 
be efficacious as monotherapy, PI3K/
AKT/mTOR inhibitors might be useful as 
combination therapy in metastatic TNBC 
patients. Reports from ongoing phase II 
studies will improve our understanding 
on the best way to utilize these drugs in 
treating TNBC.
DISCUSSION
Studies from the past two decades 
have revealedthe complexity and 
heterogeneity of TNBC. Expression and 
mutation of various genes are known to 
have prognostic value and cause different 
response towards chemotherapy, 
explaining the disparity of survival 
between race and ethnic groupsin TNBC. 
This issue is especially problematic 
for a country such as Indonesia, which 
population is not only numerous (4th 
most numerous in the world), but also 
heterogenous (comprised of more than 
730 ethnic groups). According to genetic 
pattern and anthropological analysis, 
Indonesian population has ancestral 
lineage stemming from China, India, and 
Africa, resulting in genetically unique and 
diverse population.116 Potential solution 
for this problem is by implementation 
of targeted therapy which would allow 
for a more personalized medicine. 
Unfortunately, targeted therapy in 
Indonesia is still very expensive and 
not covered by Indonesian National 
Insurance, thus chemotherapy is still the 
more suitable approach at the moment.
TNBC is associated with higher 
sensitivity towards chemotherapy 
treatment compared to other subtypes, 
albeit is also associated with higher 
rate of recurrence and distant 
metastasis.117-119 Liedtke et al,120 observed 
that TNBC patients who received NAC 
treatment achieved higher rate of pCR 
when compared to non-TNBC patients 
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(22vs. 11%; p=0.034) but had decreased 
three-year progression-free survival 
rates (p=0.0001) and three-year overall 
survival (OS) rates (p=0.0001). However, 
similar survival is observed between 
non-TNBC patients and TNBC patients if 
pCR is achieved. The association between 
pCR status and improved survival was 
later confirmed by.121 Cortazar et al.121 
performed meta-analysis and found 
that TNBC patients had the strongest 
association between pCR and event-free 
survival (EFS) (HR 0.39, 95%CI: 0.31-0.50) 
with the weakest association shown in 
HER2-positive, hormone positive subtype 
(HR 0.58, 95%CI: 0.42-0.82). Although all 
of the chemotherapy regimens used in 
treating breast cancer in general can 
be used in treating TNBC, platinum-
based regimen is observed to be the best 
regimen for TNBC patients in Indonesia, 
especially for patients expressing BRCA 
mutation.
Targeted immunotherapy such as 
PD-1/PD-L1 inhibitor has proven to be 
useful in TNBC patients, both given as 
single agent, as well as in combination 
with chemotherapy. The effectiveness 
of PD-1/PD-L1 inhibitor has resulted in 
increased research interest in finding 
more immune checkpoints as potential 
target for therapy in TNBC, including 
CD73 andCDCP1.122
CONCLUSION 
Heterogeneity of TNBC makes it 
impossible for the development of “one 
for all” treatment. Response towards 
existing treatment modalities has 
been diverse across all TNBC subtypes. 
Although, there isnot a single target 
molecule which is highly expressed in 
all of TNBC patients, targeted therapy, 
especially PD-1/PD-L1 inhibitor, has 
shown promising results but still require 
further validation through phase III and 
IV clinical trials.
Reports have shown that race and 
genetic profile are important risk factors 
and prognostic factors of TNBC. While 
research in Europe, East Asia and USA is 
numerous, TNBC research in Southeast 
Asia, especially in Indonesia is still 
far from adequate thus limiting our 
knowledge on how applicable research 
results from other countries to highly 
heterogeneous Indonesian patients.
Before breakthrough in clinical research 
can be made, it is imperative for Indonesia 
to strengthen its epidemiological 
and molecular data. An ongoing 
collaboration between International 
Agency for Research on Cancer (IARC) 
and Dr. Sardjito General Hospital, 
Yogyakarta for the development of 
population-based cancer registry (PBCR)
serves as an important stepping stone to 
reach that goal. It is also important for 
Indonesia to improve its efficiency on 
conducting clinical research. Instead of 
conducting multiple conventional trials 
assessing 1 treatment regimen at a time, 
implementation ofcentrally coordinated 
research through a platform similar 
to the one used in I-SPY 2 trial can 
substantially increase clinical research 
output as it allows for assessment of 
multiple treatment regimens at the same 
time.Further improvement on research 
efficiency can be doneby shifting from 
adjuvant to neoadjuvant chemotherapy 
as pCR has been proven by other studies 
as a predictor that can be done for long-
term survival in TNBC.
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